New biomarker could flag tumors that are sensitive to common diabetes drug

(Van Andel Research Institute) A newly identified biomarker could help scientists pinpoint which cancers are vulnerable to treatment with biguanides, a common class of medications used to control blood sugar in Type 2 diabetes.